PHIN-214 for Liver Cirrhosis

"Per PharmaIN, the sponsor of this clinical trial, the primary outcome will be observed over a two week period and concerns dose limiting toxicities. In addition to this metric, there are three secondary outcomes that need to be measured: plasma concentration of PHIN-214 (PK), AUC of PHIN-214 (AUC) and AUC of its metabolite."

"This medical trial calls for applicants aged 18-70. For minors and seniors, there are 76 trials and 444 trials respectively that they may qualify for."

"Affirmative. According to clinicaltrials.gov, the investigation that was made available on March 1st of this year is still recruiting individuals. 13 participants are needed to be recruited from 2 sites and the trial's entry has recently been refreshed as of September 8th, 2022."

"As of now, this medical trial is looking for 13 candidates with ascites between 18 and 70 years old. Eligibility requires a body mass index within the range of 18 to 40 kg/m2 at screening; females must be non-pregnant or capable of conceiving but using highly efficient contraception; patients should have liver cirrhosis confirmed by reliable biopsy (within 12 months) or Fibroscan reading beyond 15 kPa at the start."

"Affirmative, clinicaltrials.gov confirms that this research endeavour is presently enrolling individuals. It was initially announced on March 1st 2022 and further amended on August 9th of the same year. 2 sites need to recruit 13 subjects a piece in total."

"Our team at Power gave PHIN-214 Subcutaneous injection a score of 1, indicating that there is limited evidence to support the safety and efficacy of this drug given it's in Phase 1."